As the Department of Veterans Affairs (VA) seeks to enhance its digital transformation efforts, one of its key focus areas is enhancing and streamlining clinical and administrative workflows in radiology.
Read More
DSS is proud of the recent success and accolade of one of the Veterans Affairs Medical Centers (VAMC) it supports in delivering patient safety and quality Veteran care through innovative health care solutions. As reported in the Lebanon Daily News, the Lebanon VAMC won the Best Patient Experience award for level 2 facilities in the VA for three straight years.
Read More
We are excited to announce the launch of scheduling and day-of-procedure support for VA hospital service lines, including cardiology, endoscopy, pulmonology, and radiology, with LiveData Procedure Suite Manager™.
Read More
At the recent ACHE 2024 Congress, Dr. Shereef Elnahal, Under Secretary for Health for the VA, shared the most impactful and innovative approaches for enhancing #Veteran care. Here’s our summary of his presentation and how DSS is a catalyst for supporting these efforts.
Read More
As a solutions provider, integrator, and professional services contractor, DSS is fully align with the VA’s FY24 full lifecycle acquisition approach around people, processes and technologies.
Read More
Every Veteran deserves quality health care and patient safety everywhere, every day. We owe it to their service to our country. Throughout the years, DSS has led the way in supporting Veterans through health care innovation and patient care.
Read More
The VA needs to continue to invest in, maintain, and upgrade VistA as part of its EHRM efforts, according to a recent DSS-authored Federal News Network Op-Ed.
Read More
Emotion AI can be especially valuable in supporting the mental healthcare needs of Veterans and their families, as highlighted our latest Fed Health Forward podcast interview.
Read More
At ID Week 2022, VA executives presented a poster session titled, highlighting how high-risk patients with mild to moderate disease were identified as a group who would benefit from COVID-19 monoclonal antibody (mAB) treatment to mitigate progression to severe disease or hospitalization.
Read More